Результаты поиска

Oroxylin A: A Promising Flavonoid for Prevention and Treatment of Chronic Diseases.

There have been magnificent advancements in the understanding of molecular mechanisms of chronic diseases over the past several years, but these diseases continue to be a considerable cause of death worldwide. Most of the approved medications available for the prevention and treatment of these diseases target only a single gene/protein/pathway and are known to cause severe side effects and are less effective than they are anticipated. Consequently, the development of finer therapeutics that outshine the existing ones is far-reaching. Natural compounds have enormous applications in curbing seve

Diagnosis and management of neutropenia in adults: Expert guidance.

Neutropenia in general is defined as a blood neutrophil count of less than 1.5 × 109/L, in severe neutropenia counts drop to less than 0.5 × 109/L, but the definition of neutropenia varies according to the patient's ethnic origin and age. For Caucasian adults, the absolute neutrophil count (ANC) threshold of 1.8 × 109/L is adopted for the definition of neutropenia according to the World Health Organization (see Fioredda et al. (1)). It can be inherited or acquired, and it is an uncommon haematological finding in adult outpatient clinics. Neutropenia can result from decreased production of neut

Real-world treatment utilization in adults with chronic inflammatory demyelinating polyneuropathy in the United States.

BackgroundManagement of chronic inflammatory demyelinating polyneuropathy (CIDP) is challenged by heterogeneity in severity, comorbidities, potential adverse effects, and treatment accessibility. This study aimed to elucidate treatment utilization among patients with CIDP in the United States (US) to identify potential unmet needs.MethodsAdult patients with CIDP were identified using Komodo Health's Healthcare Map™ (January 2016-December 2020). Descriptive statistics related to utilization of CIDP treatments over 1-year post-index were analyzed. Among patients who used immunoglobulin (Ig), chr

Total adenosine deaminase cases as an inflammatory biomarker of pleural effusion syndrome.

BACKGROUND: Although inflammatory diseases commonly affect the pleura and pleural space, their mechanisms of action remain unclear. The presence of several mediators emphasizes the concept of pleural inflammation. Adenosine deaminase (ADA) is an inflammatory mediator detected at increased levels in the pleural fluid. AIM: To determine the role of total pleural ADA (P-ADA) levels in the diagnosis of pleural inflammatory diseases. METHODS: 157 patients with inflammatory pleural effusion (exudates, n = 124, 79%) and non-inflammatory pleural effusion (transudates, n = 33, 21%) were included in t

Нейродегенерация и демиелинация в мультипликационном склерозном корде: клиническая, патологическая и 7T MRI Перспектива.

Основные выводы, сделанные в отношении лиц с множественным склерозом (МС) с постепенной инвалидностью двигателя, включают атрофию спинного мозга (SC), означающую необратимую аксонную потерю и демиелинированные повреждения СК. Цель этого исследования заключалась в выявлении нейродегенеративных изменений и оценке клинического воздействия и патологических характеристик повреждений СК. МЕТОДЫ: Было проведено перекрестное исследование с использованием посмертных сегментов шейного мозга в рамках программы скоростной аутопсии Кливлендской клиники MS. Включение включало близость к центру, отсутствие т

Ремонтные механизмы центральной нервной системы: от вырастания аксона до воспроизводства.

Центральная нервная система (КНС), состоящая из мозга, спинного мозга и зрительного нерва, имеет ограниченную регенеративную способность, что создает значительные трудности в лечении неврологических расстройств. Последние достижения в области нейрофизики и нейротерапевтии ввели перспективные стратегии стимулирования восстановления CNS, особенно в контексте нейродегенеративных заболеваний, таких, как множественный склероз. В настоящем обзоре рассматривается сложная взаимосвязь между воспалением, обезвоживанием и возможностями воспоминания. Глиальные клетки, включая прекурсоры олигодендроцитов,

Characteristics of clinical trials in rare vs. common diseases: A register-based Latvian study.

BackgroundConducting clinical studies in small populations may be very challenging; therefore quality of clinical evidence may differ between rare and non-rare disease therapies.ObjectiveThis register-based study aims to evaluate the characteristics of clinical trials in rare diseases conducted in Latvia and compare them with clinical trials in more common conditions.MethodsThe EU Clinical Trials Register (clinicaltrialsregister.eu) was used to identify interventional clinical trials related to rare diseases (n = 51) and to compose a control group of clinical trials in non-rare diseases (n = 1

Alterations in Salivary Proteome following Single Twenty-Minute Session of Yogic Breathing.

Yogic breathing (YB) has been suggested to reduce stress and blood pressure and increase cognitive processes. However, alterations after YB at the molecular level are not well established. Twenty healthy volunteers were randomized into two groups (N = 10 per group): YB or attention controls (AC). The YB group performed two YB exercises, each for ten minutes, for a total of twenty minutes in a single session. AC group read a text of their choice for 20 minutes. Saliva was collected at baseline and at 5, 10, 15, and 20 minutes. Using Mass Spectrometry (MS), we initially found that 22 proteins we

Вторичные аутоиммунные дерматологические расстройства, вызываемые агентами по биологическому иммунотерапии с множественным склерозом: систематический обзор сообщений о случаях.

ONTEXT: Множественный склероз (MS) является разрушительным аутоиммунным нейродегенеративным заболеванием, в связи с которым лекарственные средства для лечения заболеваний (DMD) ассоциируются с вторичными аутоиммунными дерматологическими расстройствами. ЦЕЛИ: Данный систематический обзор докладов по конкретным делам направлен на изучение документально подтвержденных сообщений о случаях применения биологических препаратов при борьбе с нападениями с применением НР и распространением заболеваний, которые коррелируют с такими дерматологическими осложнениями. ИСТОЧНИКИ: Был проведен систематический

Реальная эффективность, стойкость, терпимость и безопасность атумумаба в клинической практике.

АИСЮ: Описание 12-month :: эффективность, стойкость, терпимость и безопасность атумумаба (ОМБ) -- высокоэффективной терапии для борьбы с заболеваниями (ДМТ) для повторного склероза (МС) в реальном мире. & МЕТОДЫ: Электронные медицинские записи пациентов, начинающих OMB с октября 2020 по август 2022 на two Был проведен обзор комплексных центров НР. Демографические показатели и характеристики болезней и 6- и 12-month Были проанализированы клинические, описанные пациентами и радиоологические показатели. РЕЗУЛЬТАТЫ: Всего 175 пациенты начали ОМБ со средним возрастом 44.9 (СД) 10.4) и продолжительн

Обычные и передовые магнитные резонансы, воображающие биомаркеры множественного склероза в мозгу.

Множественный склероз (MS) является разнородным заболеванием, и у каждого пациента MS наблюдаются различные клинические симптомы, которые отражаются в результатах магнитного резонансного изображения (MRI). Каждое поражение MS должно толковаться тщательно и оцениваться в сочетании с клиническим обследованием. МРТ играет важную роль в оценке того, как повреждения MS агрегируются в центральной нервной системе и как они меняются с течением времени. Существует несколько традиционных биомаркеров MS, которые могут использоваться для оценки каждого фенотипа MS. МРТ является полезным инструментом для п

Продольные меры в качестве прогностических биомаркеров при многоразовом склерозе: систематический обзор и мета-анализ.

СПРАВОЧНАЯ ИНФОРМАЦИЯ И ЦЕЛИ: В качестве ценного маркера для оценки воспаления и нейроаксонального дегенерации при множестве склерозов (MS) появилась томография оптической согласованности (OCT). Хотя такие традиционные маркеры, как атрофия мозга и потеря аксона, имеют решающее значение для мониторинга движения MS, их клиническое применение может быть ограничено различными факторами. Цель этого метаанализа продольных исследований заключается в оценке прогнозируемого значения пороговых значений толщины сетчатого слоя на основе OCT для мониторинга и прогнозирования развития и когнитивного сокраще

Real-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the USA.

INTRODUCTION: Multiple sclerosis (MS) is a heterogeneous disease affecting a diverse population. Compared with white people with MS (PwMS), Black PwMS have more severe disease and higher incidence of MS, whereas Hispanic PwMS experience earlier onset disease; however, MS is not adequately studied in these groups. We compared the effectiveness of fumarates across Black, Hispanic, Asian, and white PwMS. METHODS: This retrospective analysis using the Komodo Health database included PwMS. Patients with a claim for diroximel fumarate or dimethyl fumarate were followed from disease-modifying therap

Совпадение в полном тексте источника
… Patients who switched from another oral or injectable DMT such as interferon-beta, glatiramer acetate, teriflunomide, fingolimod, ponesimod, siponimod, or cladribine to fumarates therapy were eligible for inclusion. …

"Window of Opportunity" in Ocular Graft-Versus-Host Disease Treatment: Results of a Longitudinal Study and Case Reports.

ObjectiveTo perform a longitudinal study for determining the development of ocular graft-versus-host disease (oGVHD) after allogeneic hematopoietic stem cell transplant (HSCT) and report cases that illustrate the "window of opportunity" concept in oGVHD treatment.MethodsPatients (n=61) were examined at prescheduled clinic visits before HSCT and three-month intervals after HSCT for 2 years. The presence or absence of oGVHD was determined using the international chronic oGVHD consensus group diagnostic criteria. Ocular surface washings (OSW) were obtained at each visit and analyzed for cytokine

Factors Contributing to the Development of Neuropsychiatric Manifestations in Persons With Multiple Sclerosis: A Systematic Review.

Multiple sclerosis (MS) is the most common chronic demyelinating disease affecting the central nervous system (CNS) and is distinguished by neuroinflammation and neurodegeneration. It has four categories based on clinical course, with relapsing-remitting being the most common type. MS predominantly manifests with motor and sensory dysfunctions. However, neuropsychiatric manifestations such as depression, anxiety, schizophrenia, and bipolar disorder are not uncommon. Various factors may contribute to the development of these manifestations; therefore, this study aimed to unravel them. This syst

Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors.

IntroductionTreatment of recurrent primary pediatric brain tumors remains a major challenge, with most children succumbing to their disease. We conducted a prospective phase 2 study investigating the safety and efficacy of pomalidomide (POM) in children and young adults with recurrent and progressive primary brain tumors.MethodsPatients with recurrent and progressive high-grade glioma (HGG), diffuse intrinsic pontine glioma (DIPG), ependymoma, or medulloblastoma received POM 2.6 mg/m2/day (the recommended phase 2 dose [RP2D]) on days 1-21 of a 28-day cycle. A Simon's Optimal 2-stage design was

The EHA Research Roadmap: Infections in Hematology.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data.

Data on the prevalence of multiple sclerosis (MS) in France are scarce. National and regional updated estimates are needed to better plan health policies. In this nationwide study, we provided estimates of the prevalence of MS in France in 2012 and mortality rate in 2013. MS cases were identified in the French national health insurance database (SNIIRAM-PMSI) using reimbursement data for disease-modifying treatment, long-term disease status for MS, disability pension for MS, and hospitalisation for MS (MS ICD-10 code: G35). We identified 99,123 MS cases, corresponding to an overall crude preva

A case-control study of prevalence of anemia among patients with type 2 diabetes.

BackgroundAnemia is defined as a reduction in the hemoglobin concentration of blood, which consequently reduces the oxygen-carrying capacity of red blood cells such that they are unable to meet the body's physiological needs. Several reports have indicated that anemia mostly occurs in patients with diabetes with renal insufficiency while limited studies have reported the incidence of anemia in people with diabetes prior to evidence of renal impairment. Other studies have also identified anemia as a risk factor for the need for renal replacement therapy in diabetes. Understanding the pathogenes

Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study.

PURPOSE: Novel multiple myeloma (MM) therapies have increased patient longevity but are often associated with notable symptom burden. This study quantified the effect of general symptom level, specific symptoms, and treatment-related adverse events (AEs) on MM patients' health-related quality of life (HRQoL). METHODS: The European Organization for Research and Treatment of Cancer (EORTC) generic cancer questionnaire (Quality of Life Questionnaire Core 30) and MM-specific questionnaire (QLQ-MY20) were used in this study to assess patients' HRQoL. Data were collected on sociodemographics, disea